Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 1981;64:780-786

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by O'Connell, J. B.
Right arrow Articles by Gunnar, R. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by O'Connell, J. B.
Right arrow Articles by Gunnar, R. M.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*AZATHIOPRINE
*PREDNISONE
Medline Plus Health Information
*Cardiomyopathy

Circulation, Vol 64, 780-786, Copyright © 1981 by American Heart Association


ARTICLES

Immunosuppressive therapy in patients with congestive cardiomyopathy and myocardial uptake of gallium-67

JB O'Connell, JA Robinson, RE Henkin and RM Gunnar

Thirty-nine patients with idiopathic congestive cardiomyopathy underwent gallium-67 scintigraphy. Twenty had no evidence of myocardial uptake (group I) and 19 had demonstrable myocardial gallium-67 activity (group II). There was no significant difference in age, sex, duration of symptoms, antecedent viral illness, left ventricular end-diastolic pressure, pulmonary artery systolic pressure, or ejection fraction between the two groups. Fifteen patients in group II were treated with prednisone and azathioprine for a minimum of 8 months. Nine of 15 patients were clinically unchanged and gallium-67 scans remained positive (group IIa). Six patients had significant improvement and resolution of myocardial gallium-67 uptake (group IIb). The mean change in ejection fraction was +0.2% in group I, -4.8% in Group IIa, and +13.8% in group IIb. There were five deaths in group I (25% mortality), three in group IIa (33% mortality), and no deaths in group IIb. The only significant difference between patients in group IIa and those in group IIb was a greater left ventricular posterior wall thickness in group IIa patients. Twenty control patients without cardiac disease had negative gallium-67 scans. We conclude that gallium-67 myocardial scintigraphy may be a useful test for predicting the response to prednisone and azathioprine therapy.


This article has been cited by other articles:


Home page
CirculationHome page
M. Kodama, S. Zhang, H. Hanawa, M. Saeki, T. Inomata, K. Suzuki, S. Koyama, and A. Shibata
Effects of 15-Deoxyspergualin on Experimental Autoimmune Giant Cell Myocarditis of the Rat
Circulation, February 15, 1995; 91(4): 1116 - 1122.
[Abstract] [Full Text]


Home page
NEJMHome page
G. W. Dec and V. Fuster
Idiopathic Dilated Cardiomyopathy
N. Engl. J. Med., December 8, 1994; 331(23): 1564 - 1575.
[Full Text]